X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-cancer-and-ret-mutant-medullary-thyroid-cancer-both-published-in-the-new-england-journal-of-medicine-and-presented-in-a-presidential-sympo-301963757.html
https://www.fiercepharma.com/pharma/esmo-lillys-retevmo-drives-major-benefits-lung-thyroid-cancers-roche-bows-out-competition
https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer-301906139.html
https://investor.lilly.com/news-releases/news-release-details/lillys-retevmor-selpercatinib-first-targeted-therapy-demonstrate
https://www.ema.europa.eu/en/documents/overview/retsevmo-epar-medicine-overview_en.pdf
https://www.pharmaceutical-technology.com/news/chinas-selpercatinib-lung-thyroid/
https://www.prnewswire.com/news-releases/the-china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers-301644366.html
https://www.nasdaq.com/articles/lilly-:-fda-approves-retevmo-for-adult-patients-with-locally-advanced-or-metastatic-solid
https://www.prnewswire.com/news-releases/fda-approves-lillys-retevmo-selpercatinib-the-first-and-only-ret-inhibitor-for-adults-with-advanced-or-metastatic-solid-tumors-with-a-ret-gene-fusion-regardless-of-type-301630358.html
https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-esmo-congress-2022-301619783.html
https://www.prnewswire.com/news-releases/lilly-presents-updated-data-on-retevmo-selpercatinib-in-advanced-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-at-the-2022-european-lung-cancer-congress-301515462.html
https://www.pharmaceutical-technology.com/news/nice-lilly-selpercatinib-thyroid-cancer/
https://www.pharmatimes.com/news/smc_oks_three_new_meds_in_latest_decisions_1377480
https://www.clinicaltrialsarena.com/news/lilly-retevmo-antitumour-activity/
https://www.fiercepharma.com/pharma/aacr-a-tissue-agnostic-indication-for-retevmo-lilly-says-it-s-possible-ret-cancer-win
http://www.pharmatimes.com/news/mhra_authorises_lillys_ret_inhibitor_retsevmo_1365038
http://www.pharmafile.com/news/573005/lillys-cancer-drug-retsevmo-gets-uk-approval-multiple-indications
https://www.fiercepharma.com/marketing/roche-blueprint-catches-up-lilly-as-gavreto-snags-fda-thyroid-cancer-nod
https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-phase-12-data-for-retevmo-selpercatinib-in-advanced-ret-driven-lung-and-thyroid-cancers-301119216.html
https://endpts.com/a-groundbreaking-cancer-drug-nabs-fast-ok-giving-eli-lilly-boasting-rights-as-a-rival-speeds-close-behind/
https://uk.reuters.com/article/us-lilly-cancer-fda-approval/fda-approves-eli-lilly-drug-for-thyroid-lung-cancers-driven-by-a-genetic-mutation-idUKKBN22K2WZ?rpc=401&
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-lung-and-thyroid-cancers-certain-genetic-mutation-or-fusion
https://www.prnewswire.com/news-releases/lilly-receives-us-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-for-patients-with-advanced-ret-driven-lung-and-thyroid-cancers-301056099.html
https://www.prnewswire.com/news-releases/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application-300995006.html
Market Place
Share 
